NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025)
NuCana (NCNA) reported Net Income towards Common Stockholders of -$3.7 million for Q4 2025, down 339.46% on a YoY basis from $1.5 million in Q4 2024, and down 871.39% sequentially from -$379170.8 in Q3 2025.
NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$3.7 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 339.46% year-over-year to -$3.7 million; the trailing twelve-month figure through Dec 2025 stood at -$39.3 million (down 62.57% YoY), and the FY2025 full-year result was -$41.8 million, down 72.06% from the prior year.
- Net Income towards Common Stockholders slipped to -$3.7 million in Q4 2025, from -$379170.8 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $12.7 million in Q2 2021 to a low of -$32.2 million in Q2 2025.
- A 5-year average of -$7.9 million and a median of -$8.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 268.77% in 2021, while the deepest fall reached 364.75% in 2021.
- Tracing NCNA's Net Income towards Common Stockholders over 5 years: stood at -$18.4 million in 2021, then rose by 3.07% to -$17.8 million in 2022, then surged by 46.71% to -$9.5 million in 2023, then jumped by 91.18% to -$838126.7 in 2024, then slumped by 339.46% to -$3.7 million in 2025.
- Business Quant data shows NCNA's Net Income towards Common Stockholders at -$3.7 million in Q4 2025, -$379170.8 in Q3 2025, and -$32.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -0.68 |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 205.99 Mn |
| 10 | NuCana | 15.22 Bn | 15.19 Bn | - | -3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.68 Mn |
| Sep 30, 2025 | -379,170.76 |
| Jun 30, 2025 | -32.17 Mn |
| Mar 31, 2025 | -3.11 Mn |
| Dec 31, 2024 | -838,126.70 |
| Sep 30, 2024 | -5.86 Mn |
| Jun 30, 2024 | -8.83 Mn |
| Mar 31, 2024 | -8.67 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | -8.48 Mn |
| Jun 30, 2023 | -6.77 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -17.83 Mn |
| Sep 30, 2022 | -5.34 Mn |
| Jun 30, 2022 | 4.90 Mn |
| Mar 31, 2022 | -11.28 Mn |
| Dec 31, 2021 | -18.39 Mn |
| Sep 30, 2021 | -11.09 Mn |
| Jun 30, 2021 | 12.70 Mn |
| Mar 31, 2021 | -13.46 Mn |